Skip to main content
SpringerLink
Log in

Osteoblastic bone metastases in breast cancer: is not seeing believing?

  • Editorial Commentary
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Nakai T, Okuyama C, Kubota T, Yamada K, Ushijima Y, Taniike K, et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging 2005;32. DOI 10.1007/s00259-005-1842-8

  2. Moon DH, Maddahi J, Silverman DH, Glaspy DH, Phelps ME, Hoh CK. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med 1998;39:431–5

    CAS  PubMed  Google Scholar 

  3. Gallowitsch HJ, Kresnik E, Gasser J, Kumnig G, Igerc I, Mikosch M, Lind P. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol 2003;38:250–6

    PubMed  Google Scholar 

  4. Yeh SD, Imbriaco M, Larson SM, Garza D, Zhang JJ, Kalaigian H, et al. Detection of bony metastases of androgen-independent prostate cancer by PET-FDG. Nucl Med Biol 1996;23:693–7

    Article  CAS  PubMed  Google Scholar 

  5. Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer: initial findings of PET with 2-Deoxy-2-[F-18] fluoro-D-glucose. Radiology 1996;199:751–6

    CAS  PubMed  Google Scholar 

  6. Kang DE, White RLJ, Zuger JH, Sasser HC, Teigland CM. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol 2004;171:1806–9

    Article  PubMed  Google Scholar 

  7. Moog F, Kotzerkr J, Reske SN. FDG PET Can replace bone scintigraphy in primary staging of malignant lymphoma. J Nucl Med 1999;40:1407–13

    CAS  PubMed  Google Scholar 

  8. Durie BG, Waxman AD, D’Agnolo A, Williams CM. Whole-body 18F-FDG PET identifies high-risk myeloma. J Nucl Med 2002;43:1457–63

    PubMed  Google Scholar 

  9. Durski JM, Srinivas S, Segall G. Comparison of FDG-PET and bone scans for detecting skeletal metastases in patients with non-small cell lung cancer. Clin Positron Imaging 2000;3:97–105

    Article  PubMed  Google Scholar 

  10. Bury T, Barreto A, Daenen F, Bartthelemy N, Ghaye B, Rigo P. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med 1998;25:1244–47

    Article  CAS  PubMed  Google Scholar 

  11. Cheran SK, Herndon II, Patz EF Jr Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. Lung Cancer 2004;44:317–25

    Article  PubMed  Google Scholar 

  12. An YS, Yoon JK, Lee MH, Joh CW, Yoon SN. False negative F-18 FDG PET/CT in nonsmall cell lung cancer bone metastases. Clin Nucl Med 2005;30:203–4

    Article  PubMed  Google Scholar 

  13. Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 1998;16:3375–9

    CAS  PubMed  Google Scholar 

  14. Morris MJ, Akhurst T, Osman I, Nunez R, Macapinlac K, Siedlecki K, et al. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 2002;59:913–8

    Article  PubMed  Google Scholar 

  15. Israel O, Militanu D, Goldberg A, Nachtigal A, Keidar Z, Bar-Shalom R, Fogelman I. PET/CT assessment of bone metastases—FDG avidity and CT patterns before and after treatment. J Nucl Med 2004;45:79P (abstract)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Guy’s, King’s and St. Thomas’ School of Medicine, Guy’s Campus, London, SE1 9RT, UK

    Ignac Fogelman

Authors
  1. Ignac Fogelman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ignac Fogelman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fogelman, I. Osteoblastic bone metastases in breast cancer: is not seeing believing?. Eur J Nucl Med Mol Imaging 32, 1250–1252 (2005). https://doi.org/10.1007/s00259-005-1869-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-005-1869-x

Keywords

Search

Navigation